Short answer
Becton Dickinson (BDX) filed its Q2 2026 10-Q quarterly report on Aug 6, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $5.0B (down 9.5% year over year) with net income of $377M.
Q2 2026 key financials · XBRL
- Revenue
- $5.0B
- −9.5% YoY · +26.2% QoQ
- Net income
- $377M
- −34.3% YoY · +221.6% QoQ
- Operating margin
- 13.3%
- EPS (diluted)
- $1.34
- −32.7% YoY · +222.9% QoQ
Source: XBRL data from the Becton Dickinson (BDX) Q2 2026 10-Q on SEC EDGAR. USD.
Becton Dickinson Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Quarterly revenue $4.983B, up 5.4% YoY from $4.726B
- Gross margin 46.4% vs 47.3% YoY; operating expenses 25.3% vs 24.6% of revenue
- Best segment Interventional revenue $1.414B, up 6.4%; worst Medical Essentials revenue $1.675B, up 4.5%
- Cash and equivalents plus short-term investments $864M; operating cash flow $2.104B through nine months
- Dividends $875M and share repurchases $2.250B; tariffs, China VoBP, vaccine demand and Middle East disruptions as headwinds
Risk Factors
- No material changes to risk factors from BD’s 2025 Annual Report
- Carried-forward risks remain unchanged; 2025 Annual Report details not provided
- $2 billion accelerated share repurchase agreements settled during May 2026
- 8,301,923 shares remaining under January 2026 repurchase authorization
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Becton Dickinson quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.